Mavacamten: treatment aspirations in hypertrophic cardiomyopathy

Lancet. 2020 Sep 12;396(10253):736-737. doi: 10.1016/S0140-6736(20)31793-1. Epub 2020 Aug 29.

Authors

Michael Papadakis¹, Joyee Basu², Sanjay Sharma²

Affiliations

¹ Cardiology Clinical Academic Group, St George's, University of London, St George's University Hospitals NHS Foundation Trust, London SW17 0RE, UK. Electronic address: mipapada@sgul.ac.uk.
² Cardiology Clinical Academic Group, St George's, University of London, St George's University Hospitals NHS Foundation Trust, London SW17 0RE, UK.

PMID: 32871101
DOI: 10.1016/S0140-6736(20)31793-1

No abstract available

Publication types

Comment

MeSH terms

Benzylamines
Cardiomyopathy, Hypertrophic*
Double-Blind Method
Humans
Uracil / analogs & derivatives

Substances

Benzylamines
MYK-461
Uracil